AUS Peptide Supply

The early access event

Black
Friday.

20%OFF

Storewide. Starting now.

Early Black Friday

Your favourites.
An earlier saving.

Get 20% off all APS products. Sale prices are already applied, so you can get straight to shopping.

  • No discount code needed
  • Stacks with volume savings
  • Save up to 32% on eligible quantities
Shop the sale

APS products only. Partner offers excluded. Shipping and payment fees calculated at checkout.

The Research Journal.Peptide science, in perspective.
Evidence dossierPublished Updated Version 1.0

ARA-290 (Cibinetide) research guide

Erythropoietin-surface-inspired eleven-residue research peptide

How ARA-290 was developed from an erythropoietin structural surface, what small clinical studies measured, and why sample identity remains a separate question.

AUS Peptide Supply editorial team
ARA290cibinetide

01 · Identity

What the name identifies

ARA-290, also called cibinetide, is an eleven-amino-acid peptide developed from an erythropoietin structural motif. The design work concerned the outward-facing helix B surface rather than the entire protein. The molecule and a supplied research preparation still require their own identity evidence.

02 · Evidence position

What the literature can support

Preclinical design studies and small exploratory human trials investigate distinct questions. A condition-specific symptom signal cannot establish universal tissue repair, general pain relief or the safety and activity of a separate catalogue vial.

03 · Study-level map

Evidence and its limits

Preclinical

What was the design principle?

The 2008 work developed peptides inspired by the tertiary structure of erythropoietin and evaluated them in experimental injury models.

Limit: The design and experimental findings do not establish the effect of any material merely carrying the ARA-290 label.

Human early-phase

Were all outcomes favourable in the early sarcoidosis trial?

A 2012 double-blind placebo-controlled pilot enrolled 22 participants. The small-fibre symptom score improved relative to placebo, while pain-intensity and fatigue scores improved similarly in both groups.

Limit: The small sample, selected condition and differing endpoints limit generalisation. The trial did not evaluate APS material.

Preclinical

Where is the cibinetide alias used?

A 2023 primary study names ARA290 as cibinetide and describes an eleven-amino-acid peptide while examining age-associated cardiac measures in rats.

Limit: An animal model does not establish a human healthspan effect or validate a supplied batch.

04 · Analytical context

Questions a batch record should answer

  1. 01Does the analytical record identify the expected peptide and terminal form rather than full-length erythropoietin?
  2. 02Does an identity result accompany the reported purity measurement?
  3. 03Are sample content, counter-ion and current stock traceability documented independently?

05 · Boundary conditions

What this record does not establish

  • A molecular design objective is not a guaranteed product effect.
  • Small, indication-specific pilot results leave broad efficacy and long-term safety unresolved.
  • No verified APS CoA is available for the associated product at publication.

Sources checked

  1. 1.
    Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin

    Brines et al. — Proceedings of the National Academy of Sciences / PubMed Central · 2008 · Primary study

  2. 2.
  3. 3.

Continue through the topic